Oct 9, 2018
Celgene hat aktuell mit Otezla rd. 1,5 Mrd. $ Umsatz p.a.
Eine Studie zur erweiterten Nutzung von Otezla der Phase 3 ( also kurz vor einer Zulassung ) hat den Endpunkt erreicht.
Kurs aktuell 86,50 $
seen from Türkiye
seen from Malaysia
seen from China
seen from Malaysia
seen from T1
seen from Romania
seen from China
seen from China
seen from Russia
seen from United Kingdom
seen from Jordan
seen from United States
seen from Jordan
seen from Malaysia
seen from Kazakhstan
seen from China
seen from Malaysia
seen from United Kingdom
seen from France
seen from Jordan
Celgene hat aktuell mit Otezla rd. 1,5 Mrd. $ Umsatz p.a.
Eine Studie zur erweiterten Nutzung von Otezla der Phase 3 ( also kurz vor einer Zulassung ) hat den Endpunkt erreicht.
Kurs aktuell 86,50 $
When I was diagnosed with cancer, I set out to understand why a single pill of Revlimid cost the same as a new iPhone. I’ve covered high dru
Pfizer is buying a cancer biotech in one of the biggest pharma deals in history Pharmaceutical giant Pfizer is buying Seagen, a biotech company making a novel type of cancer treatment. Pfizer has agreed to pay $43 billion in cash, or $229 per share, making the transaction one of the largest pharma deals in history.Read more... https://qz.com/pfizer-buys-seagen-one-of-biggest-pharma-deals-ever-1850219258
Bristol Myers lymphoma therapy acquired in Celgene deal wins FDA nod
Bristol Myers lymphoma therapy acquired in Celgene deal wins FDA nod
A Bristol Myers Squibb cancer immunotherapy that the pharmaceutical giant obtained via its Celgene acquisition was awarded FDA approval Friday, adding one more of this type of personalized medicine as a treatment option for certain forms of lymphoma. The FDA approved the therapy, lisocabtagene maraleucel, as a treatment for adults who have certain types of non-Hodgkin lymphoma, including…
View On WordPress
Bristol Myers Squibb execs tout progress on Zeposia, Reblozyl and Onureg launches #bmsemployee #celgene “Though it's still integrating its Celgene buy, Bristol Myers Squibb already looks quite different than it did this time last year. One reason for that? New drug launches that not only moved from the pipeline column to the FDA-approved portfolio, but also saw their rollouts revamped by the COVID-19 pandemic. Reblozyl, approved in April to treat anemia in adults with lower-risk myelodysplastic syndromes, has seen early uptake from a “bolus” of patients who were awaiting a treatment option, CFO David Elkins told analysts. The drugmaker is “very encouraged” by demand, he added, and is in the very early stages of launches in other countries. The med scored approval to treat anemia in adults with beta thalassemia last November, and it's the most commercially successful drug among BMS’ new launches so far. It pulled in $96 million in the third quarter and $159 million so far this year. “ #medicalscienceliaison #medicalaffairs #pharmacists https://www.instagram.com/p/CHPUl3bD1NL/?igshid=ke13umladhcw
Computer Assisted Coding (CAC) Systems Market 2020: Potential growth, attractive valuation make it is a long-term investment | Know the COVID19 Impact | Top Players: 3M Health Information Systems, OptumInsight, McKesson, Nuance Communications, Cerner, Dolbey Systems, Exeltis USA, Valeant, Incyte, Celgene, etc.
Computer Assisted Coding (CAC) Systems Market 2020: Potential growth, attractive valuation make it is a long-term investment | Know the COVID19 Impact | Top Players: 3M Health Information Systems, OptumInsight, McKesson, Nuance Communications, Cerner, Dolbey Systems, Exeltis USA, Valeant, Incyte, Celgene, etc.
Computer Assisted Coding (CAC) Systems Market Reports provide results and potential opportunities and challenges to future Computer Assisted Coding (CAC) Systems industry growth. Computer Assisted Coding (CAC) Systems market research reports offers five-year revenue forecasts through 2024 within key segments of the Computer Assisted Coding (CAC) Systems industry.
The Global Computer Assisted…
View On WordPress
The congresswoman relentlessly grilled the former Celgene CEO for earning bonuses off the backs of cancer patients.
Josephine Harvey at HuffPost:
Rep. Katie Porter (D-Calif.) and her trusty whiteboard are at it again.
The lawmaker delivered one of her textbook takedowns during a House Committee on Oversight and Reform hearing Wednesday with current and former executives of three major drug companies. The committee is investigating the high cost of prescription drugs in the U.S.
Porter began her grilling of Mark Alles, the CEO of Celgene until 2019, by asking about the company’s repeated price hikes of the cancer drug Revlimid. It now costs $763 per pill ― up from $215 in 2005.
Alles explained that the drug was approved for new indications, but Porter stopped him to ask if that had changed the pill in any way.
“Did the drug start to work faster?” she asked. “Were there fewer side effects? How did you change the formula or production of Revlimid to justify this price increase?”
Alles said the manufacturing of the pill remained the same.